Literature DB >> 9548494

A cryptic T cell epitope on the apical membrane antigen 1 of Plasmodium chabaudi adami can prime for an anamnestic antibody response: implications for malaria vaccine design.

F H Amante1, P E Crewther, R F Anders, M F Good.   

Abstract

We have investigated the proliferative and Th cell responses to the Plasmodium chabaudi adami DS homologue of the Plasmodium falciparum apical membrane Ag 1 (AMA-1), a leading malaria vaccine candidate. Immunodominant T cell epitopes were defined following immunization of BALB/c mice with Escherichia coli-expressed, refolded P. c. adami DS AMA-1 recombinant protein and testing cells from the draining lymph nodes for responses against a series of overlapping peptides spanning P. c. adami AMA-1. A limited number of major T cell sites were identified in both conserved and variable regions of the protein. Several cryptic epitopes that evoked T cell responses following immunization with peptides, but not after protein immunization, were also identified. Adoptive transfer of a T cell line specific for a conserved cryptic epitope (corresponding to residues 31-50) provided help for an anti-AMA-1 protein-specific Ab response following in vivo challenge with P. c. adami parasitized RBC, such that AMA-1-specific Abs appeared more rapidly in recipient mice than in controls. Furthermore, T cells specific for cryptic epitopes afforded partial protection against P. c. adami infection in nude mice. The identification of conserved cryptic Th cell epitopes has important implications for malaria vaccine design.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9548494

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice.

Authors:  Alberto Pinzon-Charry; Virginia McPhun; Vivian Kienzle; Chakrit Hirunpetcharat; Christian Engwerda; James McCarthy; Michael F Good
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

2.  Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against Plasmodium sporozoite challenge in a rodent model.

Authors:  Sophie Schussek; Angela Trieu; Simon H Apte; John Sidney; Alessandro Sette; Denise L Doolan
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

3.  In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.

Authors:  Michael C Kennedy; Jin Wang; Yanling Zhang; Aaron P Miles; Farideh Chitsaz; Allan Saul; Carole A Long; Louis H Miller; Anthony W Stowers
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.

Authors:  Anthony W Stowers; Michael C Kennedy; Brian P Keegan; Allan Saul; Carole A Long; Louis H Miller
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

5.  Immunization with the MAEBL M2 Domain Protects against Lethal Plasmodium yoelii Infection.

Authors:  Juliana A Leite; Daniel Y Bargieri; Bruna O Carvalho; Letusa Albrecht; Stefanie C P Lopes; Ana Carolina A V Kayano; Alessandro S Farias; Wan Ni Chia; Carla Claser; Benoit Malleret; Bruce Russell; Catarina Castiñeiras; Leonilda M B Santos; Marcelo Brocchi; Gerhard Wunderlich; Irene S Soares; Mauricio M Rodrigues; Laurent Rénia; Fabio T M Costa
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

6.  Increasing the frequency of T-cell precursors specific for a cryptic epitope of hen-egg lysozyme converts it to an immunodominant epitope.

Authors:  T H Thatcher; D P O'Brien; S Altuwaijri; R K Barth
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

7.  Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial.

Authors:  Kirsten E Lyke; Modibo Daou; Issa Diarra; Abdoulaye Kone; Bourema Kouriba; Mohamadou A Thera; Sheetij Dutta; David E Lanar; D Gray Heppner; Ogobara K Doumbo; Christopher V Plowe; Marcelo B Sztein
Journal:  Vaccine       Date:  2009-01-31       Impact factor: 3.641

8.  Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.

Authors:  Sumi Biswas; Alexandra J Spencer; Emily K Forbes; Sarah C Gilbert; Anthony A Holder; Adrian V S Hill; Simon J Draper
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

9.  Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.

Authors:  Sumi Biswas; Matthew D J Dicks; Carole A Long; Edmond J Remarque; Loredana Siani; Stefano Colloca; Matthew G Cottingham; Anthony A Holder; Sarah C Gilbert; Adrian V S Hill; Simon J Draper
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

10.  Comparative Antibody Responses Against three Antimalarial Vaccine Candidate Antigens from Urban and Rural Exposed Individuals in Gabon.

Authors:  Roméo-Karl Imboumy-Limoukou; Sandrine Lydie Oyegue-Liabagui; Stella Ndidi; Irène Pegha-Moukandja; Charlene Lady Kouna; Francis Galaway; Isabelle Florent; Jean Bernard Lekana-Douki
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2016-11-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.